Fig. 1From: Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trialStudy flow-chart with number of patients screened, randomized and completersBack to article page